Figure 3.

Survival outcomes for patients who received treatment after chimeric antigen receptor T‐cell therapy progression. (A) Progression‐free survival (PFS) for all patients who received treatment (N = 237). (B) PFS according to the type of first subsequent therapy. (C) Overall survival according to the type of first subsequent therapy. BsAbs, bispecific antibodies; CI, confidence interval; CT, chemotherapy; HR, hazard ratio; ICI, immune checkpoint inhibitors; LENA, lenalidomide; POLA, polatuzumab–bendamustine–rituximab; RT, radiotherapy.